161 related articles for article (PubMed ID: 6441709)
1. 3-0-demethyl fortimicin A: in vitro activity and interpretive zone standards for disk diffusion susceptibility tests.
Barry AL; Jones RN; Thornsberry C; Gavan TL; Gerlach EH; Sommer HM
Eur J Clin Microbiol; 1984 Dec; 3(6):531-7. PubMed ID: 6441709
[TBL] [Abstract][Full Text] [Related]
2.
Castanheira M; Davis AP; Mendes RE; Serio AW; Krause KM; Flamm RK
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866862
[TBL] [Abstract][Full Text] [Related]
3. [Comparative activity of habekacin and 4 other aminoglycosides against gram-negative bacilli. Evolution of resistance].
Reynaud AE; Coude du Foresto B; Derriennic M; Courtieu AL
Pathol Biol (Paris); 1988 May; 36(5):435-8. PubMed ID: 3136424
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility of current clinical isolates of Pseudomonas aeruginosa and enteric gram-negative bacilli to amikacin and other aminoglycoside antibiotics.
Dámaso D; Moreno-López M; Martínez-Beltrán J; García-Iglesias MC
J Infect Dis; 1976 Nov; 134 SUPPL():S394-90. PubMed ID: 825591
[TBL] [Abstract][Full Text] [Related]
5. Fortimicin A: collaborative in vitro susceptibility. Comparison with amikacin and gentamicin against 11,840 clinical bacterial isolates.
Jones RN; Barry AL; Fuchs PC; Gavan TL; Sommers HM; Gerlach EH
Antimicrob Agents Chemother; 1979 Dec; 16(6):823-8. PubMed ID: 533262
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of aminoglycosides against clinical isolates of Acinetobacter baumannii complex and other nonfermentative Gram-negative bacilli causing healthcare-associated bloodstream infections in Taiwan.
Liu JY; Wang FD; Ho MW; Lee CH; Liu JW; Wang JT; Sheng WH; Hseuh PR; Chang SC
J Microbiol Immunol Infect; 2016 Dec; 49(6):918-923. PubMed ID: 26364729
[TBL] [Abstract][Full Text] [Related]
7. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
[TBL] [Abstract][Full Text] [Related]
8. Compound A49759, the 3-O-demethyl derivative of fortimicin A: in vitro comparison with six other aminoglycoside antibiotics.
Jones RN; Thornsberry C; Barry AL; Packer RR; Baker CN; Badal RE
Antimicrob Agents Chemother; 1980 Nov; 18(5):773-9. PubMed ID: 7447431
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility of recently isolated gram-negative bacteria to gentamicin, sisomicin, tobramycin, and amikacin.
Knothe H
J Infect Dis; 1976 Nov; 134 SUPPL():S271-4. PubMed ID: 825585
[TBL] [Abstract][Full Text] [Related]
10. Ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disks.
Barry AL; Fass RJ; Anhalt JP; Neu HC; Thornsberry C; Tilton RC; Painter BG; Washington JA
J Clin Microbiol; 1985 Jun; 21(6):880-3. PubMed ID: 3159749
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the AutoMicrobic system for susceptibility testing of aminoglycosides and gram-negative bacilli.
Hindler JA; Bruckner DA
J Clin Microbiol; 1987 Mar; 25(3):546-50. PubMed ID: 3571458
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of netilmicin, gentamicin, tobramycin and amikacin against glucose fermenting and nonfermenting bacteria.
DiPersio JR; Krafczyk TL
Chemotherapy; 1980; 26(5):323-33. PubMed ID: 7389428
[TBL] [Abstract][Full Text] [Related]
13. Fortimicins A and B, new aminoglycoside antibiotics. IV. In vitro study of fortimicin A compared with other aminoglycosides.
Girolami RL; Stamm JM
J Antibiot (Tokyo); 1977 Jul; 30(7):564-70. PubMed ID: 19409
[TBL] [Abstract][Full Text] [Related]
14. A laboratory assessment of the activities of four aminoglycosides.
Schrire L; Robinson RG; Koornhof HJ
S Afr Med J; 1984 Jun; 65(23):922-4. PubMed ID: 6427946
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of Ro 19-5247 (T-2525) and interpretive criteria for disk diffusion susceptibility testing.
Beskid G; Fallat V; Siebelist J; Durkin JW; Lipschitz ER; McGarry DH
J Clin Microbiol; 1987 Jul; 25(7):1186-90. PubMed ID: 3112176
[TBL] [Abstract][Full Text] [Related]
16. Reliability of a disk diffusion method using semiconfluent growth in the determination of aminoglycoside resistance.
Huovinen P; Herva E; Katila ML; Klossner ML; Renkonen OV; Toivanen P
Acta Pathol Microbiol Immunol Scand B; 1986 Jun; 94(3):153-7. PubMed ID: 3739715
[TBL] [Abstract][Full Text] [Related]
17. Proposed zone standards for interpretation of fortimicin A disk diffusion tests.
Barry AL; Thornsberry C; Jones RN
J Clin Microbiol; 1983 Aug; 18(2):440-2. PubMed ID: 6619294
[TBL] [Abstract][Full Text] [Related]
18. Resistance of gram-negative bacilli and staphylococci from blood cultures to aminoglycoside antibiotics. Comparison of 3 in vitro investigations from Austria 1982-1988.
Mittermayer H; Rotter M; Breitfellner G; Riezinger F; Thiel W; Binder L; Watschinger R
Zentralbl Bakteriol; 1990 Apr; 272(4):448-57. PubMed ID: 2113808
[TBL] [Abstract][Full Text] [Related]
19. N-formimidoyl thienamycin: in vitro comparison with cefoxitin and tobramycin against clinical, bacterial isolates.
Digranes A; Dibb WL; Benonisen E
Acta Pathol Microbiol Immunol Scand B; 1983 Apr; 91(2):141-4. PubMed ID: 6603093
[TBL] [Abstract][Full Text] [Related]
20. Wide variability in Pseudomonas aeruginosa aminoglycoside results among seven susceptibility testing procedures.
Staneck JL; Glenn S; DiPersio JR; Leist PA
J Clin Microbiol; 1989 Oct; 27(10):2277-85. PubMed ID: 2511223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
